OTCMKTS:MCUJF Medicure Q2 2025 Earnings Report $1.91 0.00 (-0.03%) As of 10:43 AM Eastern ProfileEarnings History Medicure EPS ResultsActual EPS-$0.06Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMedicure Revenue ResultsActual Revenue$4.82 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMedicure Announcement DetailsQuarterQ2 2025Date8/20/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsMedicure's next earnings date is estimated for Thursday, November 19, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Medicure Earnings HeadlinesMedicure Inc (MCUJF) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Acquisitions ...May 26, 2026 | finance.yahoo.comMedicure, Inc.: Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference CallMay 21, 2026 | finanznachrichten.deBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25.September 24 at 1:00 AM | Paradigm Press (Ad)Medicure Inc (MCUJF) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Rising LossesApril 28, 2026 | finance.yahoo.comMedicure, Inc.: Medicure Reports Financial Results for Quarter Ended September 30, 2025November 20, 2025 | finanznachrichten.deMedicure Completes Acquisition of West Olympia PharmacyJune 17, 2025 | tipranks.comSee More Medicure Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Medicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Medicure and other key companies, straight to your email. Email Address About MedicureMedicure (OTCMKTS:MCUJF) is a Winnipeg, Manitoba-based specialty pharmaceutical company focused on developing, commercializing and distributing therapies for cardiovascular and related medical conditions. The company serves healthcare markets primarily in North America through its operating subsidiaries and commercial partners. Medicure’s product portfolio includes AGGRASTAT (tirofiban hydrochloride), an intravenous antiplatelet medication used in the treatment of certain patients with acute coronary syndrome and during percutaneous coronary intervention. The company also markets ZYPITAMAG (pitavastatin), an oral statin used to help manage elevated cholesterol levels. Medicure has historically concentrated on specialty cardiovascular products and has sought to expand its presence through product development, licensing and commercialization activities. The company is led by Dr. Albert D. Friesen, who serves as president and chief executive officer.View Medicure ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
